Page 11 - FLIPBOOK

M1 docetaxel: Survival

Results based on 2992 men / 1271 deaths

Trial name

CHAARTED
GETUG15
STAMPEDE (SOC +/- Doc)
STAMPEDE (SOC+ ZA +/- Doc)
Overall HR=0.77 (0.68, 0.87) p<0.0001

.5 1 2
Favours SOC + docetaxel Favours SOC

2
2
Heterogeneity: =4.80, df=3, p=0.187, I = 37.5%
9% absolute improvement in survival

(from 40% to 49%) at 4 years

Doc, docetaxel; HR, hazard ratio; M1, metastatic disease; SOC, standard of care; ZA, zoledronic acid.
Vale CL, et al. Lancet Oncol. 2016;17(2):243–256.